National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anti-KIR monoclonal antibody 1-7F9
A human monoclonal antibody directed against the human inhibitory killer IgG-like receptor (KIR) with potential immunostimulating and antineoplastic activities. Anti-KIR monoclonal antibody 1-7F9 binds to the KIR receptor expressed on human natural killer (NK) cells, which may prevent KIR-mediated inhibition of NK cells and permit NK cell-mediated anti-tumor cytotoxicity. KIRs are surface glycoproteins that bind to major histocompatibility complex (MHC)/human leukocyte antigen (HLA) class I subtypes on target cells; binding of KIRs inhibits NK cell-mediated cytotoxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:anti-IGF-1R recombinant monoclonal antibody BIIB022, anti-IGF-1R recombinant monoclonal antibody MK-0646, anti-IGF-1R recombinant monoclonal antibody SCH 717454, anti-IL-13 humanized monoclonal antibody TNX-650, anti-IL-6 chimeric monoclonal antibody
Next:anti-myeloma cell surface antigen immunoconjugate BT-062, anti-p53 T-cell receptor-transduced peripheral blood lymphocytes, anti-PD-1 human monoclonal antibody MDX-1106, anti-PD-1 monoclonal antibody CT-011, anti-PD-L1 monoclonal antibody MDX-1105

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov